Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Core Insights - Clearmind Medicine Inc. has welcomed the inclusion of its proprietary compound MEAI in U.S. federal legislation for the first time, specifically in the Expanding Veterans' Access to Emerging Treatments Act of 2026 [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including Alcohol Use Disorder [5] - The company has a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [6] Legislative Context - The Expanding Veterans' Access to Emerging Treatments Act of 2026 directs the Department of Veterans Affairs to establish a research and treatment program for innovative therapies addressing unmet medical needs in veterans [2] - The bill explicitly includes therapies such as psilocybin, MDMA, MEAI, and others, which could lead to VA-supported clinical trials and extended access protocols for various conditions [3] Industry Impact - The inclusion of MEAI in the legislation is seen as a significant milestone, potentially transforming clinical treatment for veterans suffering from conditions like alcoholism and PTSD [4] - The recognition of MEAI highlights a growing support for innovative, evidence-based approaches to mental health treatment [4]